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Variability inWorkingMemory Performance Explained
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IMPORTANCE We investigated the variation in neuropsychological function explained by risk
alleles at the psychosis susceptibility gene ZNF804A and its interacting partners using single
nucleotide polymorphisms (SNPs), polygenic scores, and epistatic analyses. Of particular
importance was the relative contribution of the polygenic score vs epistasis in variation
explained.
OBJECTIVES To (1) assess the association between SNPs in ZNF804A and the ZNF804A
polygenic score with measures of cognition in cases with psychosis and (2) assess whether
epistasis within the ZNF804A pathway could explain additional variation above and beyond
that explained by the polygenic score.
DESIGN, SETTING, AND PARTICIPANTS Patients with psychosis (n = 424) were assessed in
areas of cognitive ability impaired in schizophrenia including IQ, memory, attention, and
social cognition. We used the Psychiatric GWAS Consortium 1 schizophrenia genome-wide
association study to calculate a polygenic score based on identified risk variants within this
genetic pathway. Cognitive measures significantly associated with the polygenic score were
tested for an epistatic component using a training set (n = 170), which was used to develop
linear regressionmodels containing the polygenic score and 2-SNP interactions. The
best-fitting models were tested for replication in 2 independent test sets of cases: (1) 170
individuals with schizophrenia or schizoaffective disorder and (2) 84 patients with broad
psychosis (including bipolar disorder, major depressive disorder, and other psychosis).
MAIN OUTCOMES ANDMEASURES Participants completed a neuropsychological assessment
battery designed to target the cognitive deficits of schizophrenia including general cognitive
function, episodic memory, working memory, attentional control, and social cognition.
RESULTS Higher polygenic scores were associated with poorer performance among patients
on IQ, memory, and social cognition, explaining 1% to 3% of variation on these scores (range,
P = .01 to .03). Using a narrow psychosis training set and independent test sets of narrow
phenotype psychosis (schizophrenia and schizoaffective disorder), broad psychosis, and
control participants (n = 89), the addition of 2 interaction terms containing 2 SNPs each
increased the R2 for spatial working memory strategy in the independent psychosis test sets
from 1.2% using the polygenic score only to 4.8% (P = .11 and .001, respectively) but did not
explain additional variation in control participants.
CONCLUSIONS AND RELEVANCE These data support a role for the ZNF804A pathway in IQ,
memory, and social cognition in cases. Furthermore, we showed that epistasis increases the
variation explained above the contribution of the polygenic score.
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G enome-wideassociation studies (GWASs)havebeenatthe forefrontof identifyingcandidategenes for schizo-phrenia.Oneof thegeneticvariantsachievinggenome-
wide significance for psychosiswas rs1344706 in the zinc fin-
ger binding protein 804A (ZNF804A).1 Several independent
replication studies2,3 and a recent meta-analysis4 have sup-
ported an association between schizophrenia and the risk al-
lele of this single nucleotide polymorphism (SNP). The gene
ZNF804A, which is expressed in the brain, is believed to en-
code a protein with a C2H2 zinc finger domain. This suggests
a role in the regulationof geneexpression throughDNAand/or
RNA binding.5 The gene ZNF804A has been reported to show
an association with brain activity and structure.6,7 A recent
study by Hill et al8 assessed the effects of its knockdown on
the cellular transcriptome, which linked ZNF804A to cell ad-
hesionmolecules, suggesting a role in neuralmigration, neu-
rite outgrowth, and synapse formation, which are hypoth-
esized to be aberrant in schizophrenia.
Several studies have linked ZNF804A to cognition, based
on imaging studies,6,9 traditional neuropsychological
measures,10-12 and measures of social cognition.13,14 The re-
sults of these studies deviate fromwhatwould be expected in
thatwhile the rs1344706 risk allele appears to convey impair-
ments in cognition in control individuals based onbehavioral
and imaging studies,11,15-17 the literature points to preserved
cognition in patients.10,12,18,19 Although some studies suggest
that ZNF804A is associated with impaired social cognition in
control participants, it is uncertain whether ZNF804Amight
also confer a disadvantage to patients because only 1 study14
has assessed patients. If ZNF804A confers risk for psychosis,
whydoes the risk allele–carryingpatientpopulation showpre-
served cognitive function? The answer may lie in the impact
ofZNF804A embeddedwithin its functional pathway.Thede-
velopment of complex traits, such as psychosis, is likely to in-
volve thecontributionofa largenumberof independentand/or
interacting genetic variants, mostly of modest effect.20,21 In
case-control analyses, polygenic scores (a simple orweighted
summation of the top sets of SNPs) have been shown to pre-
dict case status in related disorders and explain a significant
percentage of variability.22 Limiting this polygenic risk score
to include variants within genes shown to be altered by
ZNF804A knockdown,8 we investigatedwhethermore of the
variance in patients’ neuropsychological function can be ex-
plained than is explainedby singlevariants.Weused thePval-
ues andodds ratios from the Schizophrenia PsychiatricGWAS
Consortium 1 (PGC1) schizophrenia case-control analysis23 to
rank SNPs for inclusion in the polygenic score. As variation in
complex traits is thought to include both polygenic and epi-
static components, we examined whether epistasis between
SNPs within the ZNF804A pathway could explain variation
above that explained by the polygenic score alone. We used
half of the narrow psychosis (schizophrenia and schizoaffec-
tive disorder) set as a training set to test for pairwise epistasis
among all SNPs included in the polygenic score, then as-
sessed whether adding these interactions to the regression
model containing thepolygenic score increased theR2 among
3 independent test sets including (1) additional narrow psy-
chosis cases, (2) broad psychosis (bipolar disorder, major de-
pressivedisorder, andpsychosis not otherwise specified), and
(3) healthy control participants.
Methods
Participants
Four hundred twenty-four cases and 89 healthy participants
who completed a full neuropsychological assessment battery
and forwhomGWASdatawere availablewere included.Cases
were clinically stable patients with a DSM-IV diagnosis of
schizophrenia (n = 282), schizoaffective disorder (n = 58), bi-
polar disorder (n = 61), major depressive disorder with psy-
chotic features (n = 11), or psychosis not otherwise specified
(n = 12) recruited from 5 sites across Ireland (Table 1). Inclu-
sion criteria required that participants were clinically stable
at neuropsychological assessment, aged 18 to65years, hadno
history of comorbid psychiatric disorder, no substance abuse
in the preceding 6 months, no prior head injury with loss of
consciousness, andnohistory of seizures. Diagnosiswas con-
firmed by trained psychiatrists using the Structured Clinical
Interview forDSM-IV-TR.24 Additional diagnostic details and
clinical sample characteristics, including symptom severity
(Scale for theAssessment ofNegative Symptoms/Scale for the
Assessment of Positive Symptoms)25,26 and medication dos-
age,aredetailedelsewhere.10Healthycontrolparticipantswere
recruited via online and poster advertising. They were aged
18 to 65 years, with no history of substance abuse in the pre-
ceding 6months, no prior head injurywith loss of conscious-
ness, no history of seizures, and no personal history of psy-
chosis or in their first-degree relatives. All assessments were
conducted in accordance with the relevant ethics commit-
tees’ approval fromeachparticipating site.All participantshad
4 grandparents born in Ireland and provided written in-
formed consent.
Cognitive Assessment
Participants completed aneuropsychological assessment bat-
tery designed to target the cognitive deficits of schizophrenia
including general cognitive function, episodicmemory,work-
ing memory, attentional control, and social cognition. Gen-
eral cognitive functioning (IQ) was measured using selected
subtests (Vocabulary, Similarities, Block Design, and Matrix
Reasoning) fromtheWechslerAdult IntelligenceScale,27 yield-
ing a full-scale, verbal, andperformance IQ. Episodicmemory
wasassessedusingthe logicalmemorysubtest fromtheWechs-
ler Memory Scale III.28 Working memory was assessed using
the spatial workingmemory task (SWM) from the Cambridge
Neuropsychological Test Automated Battery29 and letter-
number sequencing from the Wechsler Memory Scale III.28
Attentional control was assessed using the Continuous Per-
formanceTask–IdenticalPairsversion,30 the Intradimensional-
Extradimensional shift task (IDED) (CambridgeNeuropsycho-
logicalTestAutomatedBattery),29 and theSustainedAttention
to Response Task.31 Social cognition was assessed using the
Reading the Mind in the Eyes Task32 and the Internal, Per-
sonal, and Situational Attributions Questionnaire (IPSAQ),33
which yields 2 bias scores; externalizing bias (EB), which in-
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dicates a propensity to attribute positive events to oneself
rather than to other people, and a personalizing bias, which
indicates a propensity to attribute negative events to other
people rather than to situational factors.
Genotyping
Genotyping was conducted on DNA extracted from blood in
patients and saliva in control participants. Single nucleotide
polymorphismdatawere obtained from a recent GWAS using
the Affymetrix SNP Array 6.0 platform, conducted as part of
the Wellcome Trust Case Control Consortium 2, described in
detail elsewhere.34
Statistical Analysis
Polygenicscores22 forvariants locatedwithintheZNF804Apath-
waywere calculated starting with all available SNPs within 20
Kb of genes in the ZNF804A pathway8 (eTable 1 in Supple-
ment). Target alleles at these SNPswere identified as risk asso-
ciatedbasedon thePGC1GWAS.Twopolygenic scores for each
individualwerecalculated.Thecountpolygenicscorewasbased
on the simple sumof thenumberof risk-associatedalleles they
carriedaveragedacross the totalnumberofvalidgenotypes for
that individual.Theweightedpolygenic scorewasbasedonthe
count polygenic score, with the exception that each SNP was
weighted by the log of the odds ratio from the PGC1.Weused 3
P value thresholds from the PGC1 case-control analysis as ar-
bitrary thresholdsas inapreviouspolygenic analysis22 (thresh-
oldsandnumberofSNPs:P < 1.0e-05,n = 10;P < .05,n = 218;and
P < .50, n = 1525). As individual ZNF804A SNPs have been as-
sociatedwith cognition, we examinedwhether an association
observed between the pathway-based polygenic score re-
mained after removing all ZNF804A SNPs (n = 27). A subset of
theWellcomeTrust Case Control Consortium2 samplewas in-
cludedinthePGC1schizophreniacase-controlanalysis, thusthe
samples are not entirely independent. However, the outcome
of interest in the PGC1was case status, whereas in the present
study the outcome of interest was cognition in cases with
psychosis. As suggested in the supplementarymaterials of the
original polygenic score report,22 we used all genotyped SNPs
in genes within the ZNF804A pathway without pruning for
linkage disequilibrium.
Association Analysis
Polygenic Scores
Associations between ZNF804Apolygenic score and the phe-
notypes of IQ, episodicmemory,workingmemory, attention,
and social cognitionwere tested inmultiple regression analy-
ses implemented in SPSS version 1735 or theRStatistical Com-
puting Environment.36 In each case, scores for each neuro-
psychologicalphenotypewereenteredasdependentvariables,
controlling for age and sex as necessary.
Polygenic Scores Plus Epistatic Effects
Totestwhetheradditionalvariationcouldbeexplainedbyepis-
tasis beyond that explained by the polygenic score, we devel-
oped a novel approach within the context of the regression
models previously described. To reduce multiple testing, we
restrictedour search forepistasis to themodelswhere thepoly-
genic score accounted for a small, but significant, amount of
variation in theneuropsychologicalphenotype inbroadornar-
rowpsychosis including SWMstrategy, IPSAQ-EB, andperfor-
mance IQ. First, we created equal-sized training and test sets
from the narrow psychosis cases (n = 170). Second, to obtain
a stable and consistent estimate of the P value from 2-SNP in-
teractions, we took 100 bootstrap samples with replacement
fromthenarrowpsychosis training sample andperformed lin-
ear regression analysis for all possible pairs of SNPs fallingun-
der the threshold at hand (SWM threshold P ≤ .05, SNPs:
Table 1. Participant Demographics and Neurocognitive and Clinical Measures
Characteristic
Patients
Healthy Participants
(n = 89)
Psychosis Narrow
(n = 340)
Psychosis Broad
(n = 424)
Psychosis subtype, No. NA
Schizophrenia 282 282
Schizoaffective disorder 58 58
Bipolar disorder 61
Major depressive disorder 11
PNOS 12
Male:female ratio 2.6:1 2.2:1 1.4:1
Age, mean (SD), y 41.3 (12.2) 41.3 (12.4) 36.27 (12.8)
Age at onset, mean (SD), y 22.8 (7.2) 23.2 (7.5) NA
Chlorpromazine equivalent,
mean (SD), mg/d
589.8 (562.4) 555.5 (540.7) NA
SAPS/SANS, mean (SD) NA
Manic −0.18 (0.95) 0.04 (1.09)
Depression 0.16 (1.07) 0.23 (1.06)
Positive −0.02 (0.99) −0.12 (0.95)
Disorganized −0.22 (0.76) −0.31 (0.78)
Negative 0.39 (0.9) 0.32 (0.87)
Cognition: full-scale IQ, mean (SD) 89.6 (17.8) 90.3 (18.3) 124.6 (13.3)
Abbreviations: NA, not applicable;
PNOS, psychosis not otherwise
specified; SANS, Scale for the
Assessment of Negative Symptoms;
SAPS, Scale for the Assessment of
Positive Symptoms.
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n = 218; IPSAQ-EB and performance IQ threshold P < 1.0e−05,
SNPs: n = 10). For performance IQ and IPSAQ-EB, the 10 SNPs
were all on chromosome 10 and in tight linkage disequilib-
rium (range, r2 = 0.6-1.0), which led to collinearity in the in-
teractions andwerenot tested further. For SWM, the linear re-
gressionmodel in the trainingdata contained theunweighted
polygenic score plus an epistatic term, which was the prod-
uct of the risk-associated alleles at 2 SNPs. The unweighted
polygenic score was used so the alleles comprising the score
were on the same scale of measurement as those used in the
interactions; however, the use of the weighted score did not
change the results (discussedbelow).TheaveragePvalue from
the 100 replicates was used to determine which interactions
would be evaluated using the 3 independent test sets, using
an uncorrected P < .05 threshold estimated from the training
set. To account for linkage disequilibrium, a further condi-
tionwas thatonly the interactionwith thesmallestPvaluecon-
taining a particular SNPwould be tested for replication in the
independent test sets andall other interactionscontaining that
SNPwould not be considered for replication due to collinear-
ity. This led to 3 significant 2-SNP interaction terms, indepen-
dent of one another, being brought forward for replication in
the 3 test sets.R2 values on the independent test setswere cal-
culated as the square of the correlationbetween the fittedval-
ues for the test setbasedonthemodelestimatedfromthetrain-
ing data and the observed values from the test set.
Results
Demographic and Clinical Measures
Demographic and clinical characteristics for patients and
healthy participants appear in Table 1. The characteristics of
thebroadpsychosisgroupwerecomparedwith thenarrowpsy-
chosis group and with the control group using t tests. No sig-
nificant differences were observed between the narrow and
broadpsychosis groups for age, sex, age at onset, full-scale IQ,
medication dosage as measured by chlorpromazine equiva-
lents, or positive and negative symptoms, with the exception
of the mania factor where the broad psychosis group scored
significantly higher. The patient group contained signifi-
cantlymorementhanthehealthygroup,wassignificantlyolder
at the time of assessment, and had a significantly lower full-
scale IQ.
ZNF804A Pathway Polygenic Score
ZNF804Aweighted polygenic scores were associated (uncor-
rected P < .05) withmeasurements of both general and social
cognition, includingSWM, IPSAQ-EB, andperformance IQ, al-
though the effect size was moderate (1.2%-3%) (Table 2; re-
sults for all phenotypes are in eTable 2 in Supplement). Larger
ZNF804A polygenic scores were predictive of poorer perfor-
mance on performance IQ in the broad psychosis group at the
threshold of P = 1.0e−05, but did not predict performance IQ
in the narrow psychosis group (Table 2). The IPSAQ-EB dem-
onstrated significant association with the ZNF804A poly-
genic score among broad and narrowpsychosis at a threshold
of P = 1.0e−05. Patients with psychosis who had greater poly-
genic scores demonstrated a decreased IPSAQ-EB score, sug-
gesting that these patients were less likely to show what is
known as a self-serving bias: the adaptive tendency to attri-
bute causality for negative events to external factors andposi-
tive events to oneself. Amongbothnarrowandbroadpsycho-
sis groups, a higher ZNF804A polygenic score led to
significantlypoorerperformanceonSWMstrategyat a thresh-
old of P = .05.
To determine whether the polygenic score results were
powered by ZNF804A SNPs, we excluded all variants in
ZNF804Aand reassessedassociationwith thepolygenic score;
the results were virtually unchanged (Table 2), with the ex-
ception of SWM strategy, which showed a slightly reducedR2
and larger P value in the narrow psychosis set (results for all
phenotypes are in eTable 3 in Supplement).
EpistasisWithin the ZNF804A Pathway
As just described, we tested for additional variation in SWM
explained by 2-SNP epistasis in the narrowpsychosis training
set. Because of linkage disequilibrium, 112 average P values
across 100bootstrap samples of the training setwere less than
.05; however, of these, only 3 were completely independent
of the other sets and thus only these 3 interaction termswere
brought forward for replication in the 3 independent test sets.
Table 2. Significant Variance Explained (R2) and Associated PValues for ZNF804A Polygenic Score Regression on Neuropsychological Phenotypesa
Phenotype
R2 (P Value)
Narrow Psychosis Broad Psychosis
P Value Threshold
.00001 .05 .50 .00001 .05 .50
Performance IQ including
ZNF804A
0.009 (.26) 0.001 (.51) 0.002 (.41) 0.012 (.03) <0.001 (.78) 0.004 (.21)
IPSAQ-EB including
ZNF804A
0.030 (.01) 0.0070 (.21) 0.0030 (.43) 0.025 (.01) 0.0040 (.28) 0.0030 (.39)
SWM strategy including
ZNF804A
0.010 (.09) 0.017 (.03) 0.003 (.35) 0.0040 (.23) 0.013 (.03) 0.0020 (.41)
SWM strategy excluding
ZNF804Ab
0.010 (.11) 0.017 (.03) 0.003 (.36) 0.0040 (.23) 0.011 (.05) 0.0010 (.47)
Abbreviations: IPSAQ-EB, Internal, Personal, and Situational Attributions
Questionnaire–Externalizing Bias; SWM, spatial workingmemory.
a Bolded numbers indicate P < .05.
bOnly the significant P value threshold for SWM strategy (P < .05) included
ZNF804A single nucleotide polymorphisms.
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Beginningwith SWMstrategy, adding themost significant in-
teraction (rs17186340:rs140512) to the model containing the
polygenic count score led to an increase of 1.4% in the narrow
psychosis test set (P = .05), 3.7% in thebroadpsychosis test set
(P = .04), and a combined case test set increase of 2.3%
(P = .006) (Table 3). Although adding this interaction in-
creased thevariationexplained in 2 independent sets of cases,
it did not increase variation explained in control participants
(R2 = 0.0069,P = .45). Adding a second interaction term to the
model (rs2295984:rs34138673) further increased the varia-
tion explained in cases: in the narrow psychosis test set, the
R2 increased by 1.3% (P = .02) to a total of 4.0%; in the broad
psychosis test set, the R2 increased further by 1.2% (P = .04)
for a total variation explained of 6.2%; and in the combined
set of cases, the R2 increase was 1.3% (P = .001) for a total of
4.8%. In control participants, adding the second interaction
did not increase the variation explained (R2 = 0.001, P = .77).
The third epistatic term did not increase the R2 values in any
independent test set and thus was not considered further.
To test whether the increase in R2 was attributable to
strongly associated SNPs contained in the interactions them-
selves, interaction SNPs were tested individually for associa-
tion with SWM strategy in a model containing the polygenic
count score. Two SNPswere associatedwith SWM strategy at
an uncorrected P < .05 and both were in the second interac-
tion term(rs17186340:rs34138673).The improvement inR2 val-
ues from the narrow psychosis training set model containing
the polygenic count score plus rs17186340 on the narrowpsy-
chosis, broadpsychosis, and total test cases setwere 5.89e−06,
9.1e−04, and 8.0e−05, respectively. Results for the same analy-
sis using rs34138673 were 0.0056, 0.013, and 0.0079, respec-
tively, indicating that the interaction term explained more
variation than either single SNP.
To seewhether the typeof polygenic score influenced the
amount of variation explained, the weighted polygenic score
was substituted for the count polygenic score and R2 values
were calculated for the case test sets. In the narrowpsychosis
test set, the use of theweighted polygenic score in the 3mod-
els (polygenic only, 1 and2 interactions) increased theR2 value
by 9.1e−04 − 0.001 vs models containing the count polygenic
score,whereas theuseof theweightedpolygenic score inbroad
psychosis reducedtheR2valueby4.7e−04 − 0.0061vs thecount
polygenic score, suggesting the choice of polygenic scorewas
trivial in this instance.WhenstronglyassociatedSNPswithvery
large or very small effect sizes (odds ratios) are present, we
would expect to see differences between using the count or
weighted score.
Discussion
We used polygenic scores to investigate whether ZNF804A
pathway schizophrenia risk–associated alleles were associ-
ated with neuropsychological function among 424 patients
with psychosis. Higher ZNF804A polygenic scores were sig-
nificantly associatedwith poorer performance in IQ,working
memory, and biased social cognition and explained 1% to 3%
of the variation in thesemeasures, consistent with estimates
previously reported in general intelligence in control
individuals.37 Removal of the SNPswithin ZNF804A reduced
the R2 values only slightly, suggesting the combined contri-
bution of genes within the pathway was driving the associa-
tion.Furthermore,weshowed that consideringepistasis along
with the polygenic score resulted in more than 3 times the
amount of variation explained in 2 independent test sets of
cases (range, totalR2 = 4.0%-6.2%). Because the SNPspartici-
pating in interactions were not in ZNF804A, we provide fur-
ther evidence that this genewasnot thekey contributor toour
pathway-based results. Thus, our findings are not inconsis-
tentwith previous studies showingpreserved cognitive func-
tion in cases is associated with ZNF804A. Although the poly-
genic score explained a similar amount of variation in control
participants, improvements due to epistasis were specific to
psychosis cases.
Althoughprevious studies have shown that the risk allele
of ZNF804A rs1344706 showsdifferential effects in cases and
control participants,10-19we showed that, at thepathway level,
theeffectof thecombinationof schizophrenia riskalleles leads
to poorer performance in patients with psychosis on mea-
sures of intelligence, working memory, and social cognition.
The4SNPsparticipating in epistasis that increased theR2 val-
ues in our test sets were near STAC (rs17186340), MAPK8IP2
(rs140512), and flankingeither sideofFAM46A (rs2295984and
rs34138673). In mice, Stac is expressed in the brain, neurons,
and postsynaptic densities; within the brain, the expression
is highest in the hippocampus and cerebellum.38,39 A Stac
knockout mouse model showed reduced social interaction,
impaired learning, and deficits in exploration of novel
environments.39 MAPK8IP2 is located within the Chr22q13.3
deletion regionassociatedwithautismspectrumdisordersand
Table 3. Increase in R2 Values Using Epistasis in ConjunctionWith ZNF804A Polygenic Scores
Across the Narrow Psychosis Test Set and Broad Psychosis Seta
Model
Narrow
Train R2 P Value
Narrow
Test R2 P Value
Broad
R2 P Value
Total
Test
Case R2 P Value Control R2 P Value
Polygene count score 0.017 .12 0.013 .17 0.013 .34 0.012 .11 0.03 .11
Polygene count
score + rs17186340T:rs140512A
0.13 6.70e−005 0.027 .05 0.05 .06 0.035 .006 0.0069 .45
Polygene count
score + rs17186340T: rs140512A + rs2295984T:rs34138673G
0.16 2.70e−005 0.04 .02 0.062 .04 0.048 .001 0.001 .77
a Bolded numbers indicate P < .05.
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Phelan-McDermid syndrome, which is characterized by de-
velopmental delay. Also known as JIP2, it is a scaffold protein
that is necessary for N-methyl-D-aspartic acid receptor func-
tion and modulates signal transduction.40 FAM46A is ex-
pressed in adult humanbrain and showshigher expression in
human fetal brain.41 The SNPs participating in the second in-
teraction term, rs2295984andrs34138673, are locatedoneither
side of FAM46A, approximately 19.5 kbp apart, possibly indi-
cating a promoter and/or enhancer role.
How can we reconcile previous research that has shown
the risk allele at ZNF804A rs1344706 is associated with less
impaired cognition in patients with psychosis with the
results of the present study, which showed that the poly-
genic score from the ZNF804A pathway was associated with
poorer performance IQ, working memory, and social cogni-
tion? The P values from the PGC1 were used to select SNPs
for inclusion in the polygenic score, and the smallest
ZNF804A P value was .002 for rs1344706. Therefore, the set
with the most stringent threshold did not include any
ZNF804A SNPs, and this set was negatively associated with
IQ and social cognition. For working memory, the removal of
the ZNF804A SNPs at a threshold of P = .05 would have
included 12 of the 27 SNPs with P values ranging between
.002 and .05. We have shown that the removal of these SNPs
did not lead to significant differences in the magnitude of
association between the polygenic score and working
memory. The use of the weighted polygenic score would
have ensured a weak contribution of these SNPs because
they were not strongly associated with schizophrenia in the
PGC1 and they comprised only 5.5% of the total number of
SNPs at that threshold. Interestingly, the PGC1 P values for
the 4 SNPs participating in epistasis ranged between .007
(rs2295984) and .04 (rs17186340), showing that although
they are marginally associated with schizophrenia, they
would not have been considered for follow-up. As was the
case with the previous use of the polygenic score,22 we
showed that the polygenic score and epistatic models based
on a narrow psychosis training sample were able to signifi-
cantly account for variation in working memory in 2 inde-
pendent psychosis samples, but they were not able to pre-
dict variation in control participants. Although the control
sample size was modest (n = 89), the broad psychosis
sample was of a similar size (n = 84) so a lack of statistical
power cannot fully explain the inability to account for addi-
tional variation in control participants.
Interestingly, the 10 SNPs in linkage disequilibrium that
comprised the most strongly associated polygenic score for
IPSAQ-EBandperformance IQ included 5 SNPs inCNNM2 and
5 SNPs either 3′ or 5′ of the gene. This gene is strongly associ-
atedwith schizophrenia23,42,43 andwe and other groups have
shown variation within the gene is associated with graymat-
ter volume in patients with schizophrenia44,45 andwith attri-
butional style.45 Our results support a polygenic contribution
of variationwithin and around this geneweakly contributing
to attributional style and performance IQ.
We have introduced a novel method to evaluate the com-
bined effect of the polygenic score and epistasis, which is both
simple and computationally tractable. The addition of the epi-
static terms also increased the interpretability of themodel, as
it isdifficult todeterminewhichgeneswerecontributingsignal
to thepolygenic score.Weshowedthat the resultsestimatedon
thetrainingsampleweregeneralizableto2 independenttestsets
ofpatients—onewithnarrowpsychosis andtheotherwithnon-
schizophreniapsychosis—similar topreviousstudies’useof the
polygenic score.22 In both instances, the variation explainedby
our epistatic termswasmuch larger than that explained by the
polygenicscore itself: thepolygenicscoreexplained1.2%to1.3%
of variation, whereas increases in R2 using our novel approach
inthetestsetswerebetween2.7%and4.9%.Epistasis is thought
to be a key element in complex phenotypes20,21 and has been
showntoinfluencetheriskforschizophreniaandinefficientdor-
solateralprefrontal cortexprocessingduringaworkingmemory
task in healthy control individuals.20,21,46,47 The potential limi-
tations of our study includedmodest sample sizes and the fact
thatwemaynothavecapturedallvariation(especiallyrarevaria-
tion) in the genes in the ZNF804A pathway because of our reli-
ance on SNPs from a GWAS.
Conclusions
Toour knowledge, this study is the first to investigate the role
of the ZNF804A pathway in the cognitive decline commonly
observed among patients with psychosis. We have identified
3 new candidate genes for working memory in the ZNF804A
pathway: STAC,MAPK8IP2, andFAM46A. Perhapsmore criti-
cally, we introduced an improvement in the use of polygenic
scores by adding an epistatic component that explained addi-
tional variation inworkingmemory thatwas specific to cases
with psychosis.
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